GlassScriptPhysician profile
Heather L Kinder
NPI 1295240885
$1,507.88
in general payments reported to CMS, 2019-2025
25 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $525 · 2023: $452 · 2024: $147 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $192.20 | 2025 | Ultreon, Navitor |
| Novo Nordisk INC | $167.67 | 2021-2022 | |
| Amgen INC. | $163.98 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $130.75 | 2021-2022 | |
| Abbvie INC. | $103.38 | 2021-2023 | |
| Kestra Medical Technology Services, INC. | $90.00 | 2024 | Assure Wcd |
| Sumitomo Pharma America, INC. | $70.84 | 2023 | Myfembree |
| Novartis Pharmaceuticals Corporation | $64.10 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $57.91 | 2021-2022 | |
| Penumbra, INC. | $56.92 | 2024 | Indigo System |
| Organon LLC | $49.97 | 2023 | Nexplanon |
| Sanofi-Aventis U.S. LLC | $48.44 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $47.07 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.24 | 2022 | |
| Merck Sharp & Dohme LLC | $29.96 | 2023 | Gardasil 9 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28.70 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.78 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.09 | 2022 | |
| Avion Pharmaceuticals | $22.20 | 2023 | Balcoltra |
| Sanofi Pasteur INC. | $17.75 | 2022 | |
| Glaxosmithkline, LLC. | $17.24 | 2022 | |
| Medtronic, INC. | $16.47 | 2021 | |
| Pfizer INC. | $14.98 | 2022 | |
| Exeltis, USA INC. | $13.68 | 2023 | Slynd |
| Astellas Pharma US INC | $13.56 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Kinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.